drugset / Trial / NCT03695250
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer
Phase 1/2
Terminated
8 enrolled
Edward Kim
Bristol-Myers Squibb · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I/II trial studies the side effects and best dose of IDO1 inhibitor BMS-986205 (BMS-986205) when given together with nivolumab and how well it works as first or second line therapy in treating patients with liver cancer. BMS-986205 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving BMS-986205 and nivolumab may work better in treating patients with liver cancer.
Timeline
- Start
- 2018-10-16
- Primary completion
- 2020-11-24
- Completion
- 2021-03-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LINRODOSTAT | Small molecule | — | Oral |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |